Email updates

Keep up to date with the latest news and content from BMC Ophthalmology and BioMed Central.

Open Access Highly Accessed Open Badges Pre-publication history

A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

David Eveleth*, Carla Starita and Charles Tressler

BMC Ophthalmology 2012, 12:9  doi:10.1186/1471-2415-12-9

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 14 Sep 2011
Reviewer's Report Teresa Rolle 06 Nov 2011
Reviewer's Report Randy Craven 08 Nov 2011
Reviewer's Report Marcelo Hatanaka 14 Nov 2011
Resubmission - Version 2 Manuscript Author's comment 31 Jan 2012
Reviewer's Report Teresa Rolle 12 Feb 2012
Editorial acceptance 27 Feb 2012
Published 18 May 2012